Apologies for the delay in this post – the day was quite full yesterday. The Thursday presentations were quite exciting with more talk about medications to treat cavernous angiomas but also discussion of unexpected impacts of CCM mutations. Here is the list of topics and presenters:
“Loss of KRIT1 (ccm1) leads to increased vascular permeability and modifies inflammatory responses in vivo” was presented by Angela Glading of the University of Rochester.
“Defective vascular integrity upon ICAP-1/Krit1 complex loss correlates with aberrant beta 1 integrin-dependent dialog between the endothelial cell and its extracellular matrix” was presented by Eva Faurobert from Grenoble, France.
“Loss of Ccm3 in neuroglia leads to cerebral cavernous malformations and vascular pathology” was presented by Angeliki Louvi of Yale.
These three presentations were continuations of presentations from previous conferences and already published papers. They examined implications of the mutations that were not strictly related to the vascular malformations we all know.
The day’s other presentations touched on medication treatments. They were:
“CCM1 and ICAP1 induce Notch signaling ot inhibit angiogenesis. Animal models and therapeutic implications” by Andreas Fischer of Heidelberg University.
“CCM2 Regulates Superoxide and Nitric Oxide in the Endothelium” by Christopher Gibson of the University of Utah
“Fasudil Decreases Lesion Burden in a Murine Model of Cerebral Cavernous Malformation Disease” by Dave McDonald of Duke University.
While I’m not able to discuss details, I can say that there is, as yet, no perfect medication identified for treating cavernous angiomas. A challenge will be finding an effective medication that is also suitable for long term use. However, I can say that new and better techniques are being developed to evaluate potential compounds.
Some images of the day:
Angela Glading and Andreas Fischer, two of the day’s presenters discussing their work during a break:
Even though researchers are at the same institution, this doesn’t mean they have opportunity to talk about their work in as much depth as they’d like. Here Blaine Hart, Leslie Morrison and Beth Baca of the University of New Mexico have a rare chance to discuss their data.
After the day’s sessions, groups of scientists went off to enjoy some of the local sights. Here a multi-national group visits the Chateau de Chantilly. Israel, Italy, and the US are represented.
Friday is the last day of the workshop with a full day of sessions on new imaging techniques that allow for better modeling of lesions for research (3-D images and 7 Tesla SWI images are ultra-cool), clinical drug trials, and genetic and clinical studies.